Rapport Therapeutics (RAPP) Stock: Buy, Sell, or Hold?
RAPP - Rapport Therapeutics, Inc. Common Stock
$32.17
-0.66 (-2.01%)
▼
5d:
-5.13%
30d:
-33.93%
90d:
-16.59%
HOLD
MODERATE Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When RAPP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: RAPP shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: RAPP shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: RAPP is currently trading at $32.17, which is considered oversold relative to its 30-day fair value range of $35.72 to $48.44.
Technical Outlook: Technically, RAPP is in a uptrend. The price is currently testing key support at $31.58. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $62.88 (+95.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, RAPP is in a uptrend. The price is currently testing key support at $31.58. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $62.88 (+95.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$35.72 -
$48.44
Company Quality Score
57/100
(HOLD)
Options IV Signal
51th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 51th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 95.5% below Wall St target ($62.88)
- NEUTRAL: Bottoming setup forming (45/100) — watch for confirmation
- CAUTION: 5-day price weakness (-5.1%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$35.72 -
$48.44
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$5.28
(16.4%)
Support & Resistance Levels
Support Level
$31.58
Resistance Level
$42.18
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.15
Wall Street Target
$62.88
(+95.5%)
Share & Embed Analysis
Last updated: October 03, 2026 1:38 PM ET
Data refreshes hourly during market hours. Next update: 2:38 PM
Data refreshes hourly during market hours. Next update: 2:38 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RAPP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Rock Ventures V L.P. Thi…
SELL
426005 shares
2026-04-17
Krishnaswamy Yeleswaram
SELL
20225 shares
2026-04-17
Krishnaswamy Yeleswaram
SELL
10200 shares
2026-04-14
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 71 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$75 | 60 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 54 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$28 | 53 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 58 HOLD |